Updated 6/18 pre-market
Biotech Update for Week Ending 6/15
A relatively quiet less volatile week with the bullish trend intact at “triple-top” with XBI at $97 level. However, NASDAQ weakness today could blunt run in biotechs. We probably had one of the best ASCO stock rallies on record in 2018 focusing on small and mid-caps with best science and high expectations of M&A.
FBT $145.50 p 1.56%, IBB at $111.26 up 1.13%, XBI $97.18 up 0.36%.
Selective winners of the week: BMY up 3% to $54.80, JAZZ up 1.34% to $178.10, NBIX up 1.36% to $102.32, RARE up 5.64% at $82.72, SRPT up 3.64% to $102.29.
PTC Therapeutics (PTCT) was up 38% pre-market on 6/18, to the $52 level, 115% YTD on interim clinical data for Type 1 Spinal Muscular Atrophy in babies.
=======
Mid-Cap Biotech: ASCO Winners and Losers
2018: Huge Rally in Many Stocks
We updated our mid-cap biotech watch list in the first week of trading after the ASCO Meeting. Many on this list are momentum stocks driven by clinical data and biotech specialist fund support. See all of our previous articles on this subject. Here are some takeaways in what has been YTD a bull market in biotech stocks despite a lackluster year for healthcare and large cap drug stocks. As we have said before, 2018 favors small and mid-cap stocks because of clinical data impact, M&A trends and sensitivity to any positive news. Large caps are less volatile but have under-performed due to lower growth prospects and earnings concerns. Celgene (CELG) is at a 52 week low.
- As usual two biotech ETFs outperformed: FBT up 16.25% YTD and XBI up 14.2% YTD.
- Fidelity Select Biotechnology Fund (FBIOX) was up 5.79% YTD while the IBB was up 3.88%.
- Top seven winners %YTD: CRSP up 152.7, LOXO up 112.7, SRPT up 77.5, AGIO up 62.7, NVCR up 55.7, IMMU up 51.2, FMI up 47.6.
- Top seven losers %YTD: TSRO -48.8, ACAD -41.3, CLVS -38.5, EXEL -36.6, NKTR -30.7, ANAB -21.5, ALNY-16.6,
Data will be mined with further analysis later in the week.
| Company | Ticker | Price $ | Revs $B | MktCap | %Perf | Analyst | 30day | |
| 6/12/18 | $B | YTD 2018 | Rating* | % | ||||
| Acadia Pharma | ACAD | 17.67 | 0.158 | 2.2 | (41.3) | 2 | -4.74 | |
| Agio Pharma | AGIO | 93 | 0.041 | 5.42 | 62.7 | 2 | 6.77 | |
| Alnylam | ALNY | 105.91 | 0.93 | 10.8 | -16.6 | 2.2 | 4.95 | |
| Anaptys Bio | ANAB | 70.49 | 0.01 | 1.76 | -30 | 1.7 | -21.5 | |
| ArenaPharma | ARNA | 48.94 | 0.016 | 2.39 | 44 | 1.8 | -8.78 | |
| Array Biopharma | ARRY | 18.32 | 0.17 | 3.81 | 43 | 1.6 | 21.8 | |
| AveXis | AVXS | 217 | 0 | 8 | 96.2 | 2.8 |
acquired
|
|
| BlueBird Bio | BLUE | 184.75 | 0.046 | 9.5 | 3.73 | 2.2 | -0.9 | |
| Blueprint Med | BPMC | 72.35 | 0.016 | 3.38 | -4 | 1.5 | -11.24 | |
| Clovis Oncology | CLVS | 42.06 | 0.067 | 2.39 | -38.5 | 2 | -17.8 | |
| CRISPR Ther | CRSP | 59.34 | 0.039 | 2.79 | 152.7 | 2.1 | 12.54 | |
| Exelixis | EXEL | 19.28 | 0.583 | 5.87 | -36.6 | 1.9 | -1.38 | |
| Immunomedics | IMMU | 24.44 | 0.002 | 4.27 | 51.2 | 1.3 | 28.7 | |
| Incyte | INCY | 70.58 | 1.54 | 14.9 | -25.5 | 2.2 | 6.22 | |
| Ionis | IONS | 47.15 | 0.54 | 6.18 | -6.26 | 2.8 | 2.61 | |
| Amicus Ther | FOLD | 15.93 | 0.049 | 3.19 | 10.7 | 1.7 | 10.7 | |
| Foundation Med | FMI | 100.7 | 0.179 | 3.95 | 47.65 | 2.5 | 32.6 | |
| GW Pharma | GWPH | 155.12 | 0.016 | 4.37 | 17.5 | 2.3 | 6.27 | |
| Ligand Pharma | LGND | 192 | 0.168 | 4.1 | 40.22 | 2.2 | 7.74 | |
| Loxo Oncology | LOXO | 179 | 0.059 | 5.32 | 112.7 | 1.3 | 28.4 | |
| Neurocrine Bio | NBIX | 101 | 0.233 | 9.12 | 30.26 | 1.6 | 11.8 | |
| Nektar Therap | NKTR | 53.56 | 0.321 | 10.17 | -10.3 | 1.7 | -30.7 | |
| NovoCure | NVCR | 31.45 | 0.194 | 2.93 | 55.7 | 1.6 | 4.8 | |
| Seattle Genetics | SGEN | 69.21 | 0.513 | 11 | 29.4 | 2.3 | 21.6 | |
| Serepta | SRPT | 98.76 | 0.202 | 6.47 | 77.5 | 1.8 | 6.32 | |
| Tesaro | TSRO | 42.44 | 0.227 | 2.34 | -48.8 | 2 | -15 | |
| *yahoo | ||||||||
| First Trust Arca | FBT | 144.8 | 16.2 | 5.38 | ||||
| iSharesBIO | IBB | 110.9 | 3.88 | 4 | ||||
| NASDAQ-100 | QQQ | 172.74 | 3.76 | 12.9 | ||||
| SPDR S&P | XBI | 96.93 | 14.2 | 5.76 | ||||
| HC SPDR | XLV | 85.12 | 2.95 | 2.52 | ||||
| Data from FinViz | ||||||||
| and Yahoo | ||||||||
